Results 221 to 230 of about 252,888 (297)

Relapses, Comorbidities, and Predictors of Outcome in Anti‐GABAA Receptor Encephalitis

open access: yesAnnals of Neurology, EarlyView.
Objectives To characterize the magnetic resonance imaging (MRI) lesion dynamics, comorbidities, predictors of relapse, and outcomes in anti‐γ‐aminobutyric acid type A receptor (GABAAR) encephalitis, and assess the utility of LIM‐domain‐only‐protein 5 (LMO5) antibodies as tumor markers.
Claudia Papi   +33 more
wiley   +1 more source

Longitudinal Phenotypic Trajectories in GNAO1‐Related Disorders: Defining Disease Progression and Clinical Profiles

open access: yesAnnals of Neurology, EarlyView.
Objective Pathogenic variants in GNAO1 cause a spectrum of epilepsy, movement disorders, and developmental impairment. Clinical heterogeneity complicates prognosis and therapeutic development. We present the first longitudinal natural history study of GNAO1‐related disorders (GNAO1‐RD) to delineate phenotypic trajectories. Methods Sixty‐six individuals
Jana Domínguez‐Carral   +52 more
wiley   +1 more source

Use of Machine Learning to Identify Markers of Risk for Fragile X‐Associated Tremor/Ataxia Syndrome: A Preliminary Analysis

open access: yesAnnals of Neurology, EarlyView.
Objective The objective of this study was to examine whether machine learning has the capacity to prospectively identify and predict the emergence of Fragile X‐associated tremor/ataxia syndrome (FXTAS) among male fragile X premutation carriers (PCs). Methods We explored neuropsychological and motor evaluation metrics, brain magnetic resonance imaging ...
Chitrabhanu Gupta   +10 more
wiley   +1 more source

Editorial: Patient education in the treatment of chronic pain. [PDF]

open access: yesFront Pain Res (Lausanne)
Modarresi S, Shafiee E.
europepmc   +1 more source

Oxytocin‐ und Vasopressin‐Photosonden zur Entschlüsselung der Neuropeptid‐Signalgebung mit hoher räumlicher und zeitlicher Präzision

open access: yesAngewandte Chemie, EarlyView.
Neue biokompatible Oxytocin‐ und Vasopressin‐Photosonden mit modernsten Photocages. Diese Photosonden sind inaktiv und können mit spezifischen Lichtwellen entschützt werden, was eine Rezeptoraktivierung mit hoher zeitlicher und räumlicher Kontrolle ermöglicht. Abbildung erstellt mit https://BioRender.com ZUSAMMENFASSUNG Das Oxytocin/Vasopressin (OT/VP)
Konstantin Raabe   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy